Houston (1)

Acute Myeloid Leukemia (1)

Blasts 20 Percent or More of Bone Marrow Nucleated Cells (1)

High Risk Myelodysplastic Syndrome (1)

Recurrent Acute Biphenotypic Leukemia (1)

Recurrent Acute Myeloid Leukemia (1)

Recurrent High Risk Myelodysplastic Syndrome (1)

Refractory Acute Myeloid Leukemia (1)

Refractory High Risk Myelodysplastic Syndrome (1)

Recruiting (1)

phase 1/phase 2 (1)

M.D. Anderson Cancer Center (1)

National Cancer Institute (NCI) (1)

cladribine (1)

cytarabine (1)

idarubicin (1)

quizartinib (1)

drug (1)

Other (1)

Interventional (1)

blasts 20 percent or more of bone marrow nucleated cells

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Recruiting

Dec 7, 2022